Deutsche Bank AG Invests $2.33 Million in LifeStance Health Group, Inc. $LFST

Key Points

• Deutsche Bank initiated a $2.33 million position in LifeStance Health Group during the second quarter, while institutional investors collectively own 85.5% of the company.
• LifeStance reported quarterly revenue of $435.35 million, up 26.1% year over year and above estimates, while earnings of $0.06 per share exceeded the $0.03 consensus.
• Analysts maintain a “Moderate Buy” consensus with a $12.38 target price, although insiders—including major shareholder TPG—sold roughly $155 million of stock over the past 90 days.

Deutsche Bank AG bought a new position in LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 217,798 shares of the company's stock, valued at approximately $2,333,000. Deutsche Bank AG owned 0.06% of LifeStance Health Group at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Global Retirement Partners LLC acquired a new stake in LifeStance Health Group during the 2nd quarter worth approximately $572,000. Bank of New York Mellon Corp acquired a new position in LifeStance Health Group during the second quarter valued at approximately $11,626,000. Private Advisory Group LLC purchased a new stake in LifeStance Health Group during the second quarter worth approximately $386,000. State of Wyoming purchased a new stake in LifeStance Health Group during the second quarter worth approximately $736,000. Finally, Handelsbanken Fonder AB grew its stake in LifeStance Health Group by 37.0% during the second quarter. Handelsbanken Fonder AB now owns 41,100 shares of the company's stock worth $440,000 after buying an additional 11,100 shares during the period. Institutional investors and hedge funds own 85.50% of the company's stock.

LifeStance Health Group Stock Performance

Shares of LFST stock opened at $12.30 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38. LifeStance Health Group, Inc. has a one year low of $4.77 and a one year high of $12.97. The company's 50-day simple moving average is $11.13 and its 200-day simple moving average is $8.57. The stock has a market capitalization of $4.77 billion, a price-to-earnings ratio of 94.62 and a beta of 1.14.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The firm had revenue of $435.35 million during the quarter, compared to analyst estimates of $414.58 million. During the same period in the previous year, the company earned ($0.01) earnings per share. LifeStance Health Group's quarterly revenue was up 26.1% on a year-over-year basis. Equities analysts anticipate that LifeStance Health Group, Inc. will post 0.16 earnings per share for the current fiscal year.

Insider Transactions at LifeStance Health Group

In other LifeStance Health Group news, CTO Vukasin Paunovich sold 44,394 shares of LifeStance Health Group stock in a transaction on Monday, August 10th. The shares were sold at an average price of $10.85, for a total value of $481,674.90. Following the completion of the transaction, the chief technology officer owned 247,446 shares of the company's stock, valued at $2,684,789.10. The trade was a 15.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $10.62, for a total transaction of $144,890,858.34. Following the sale, the insider owned 98,101,407 shares of the company's stock, valued at approximately $1,041,836,942.34. The trade was a 12.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 14,629,850 shares of company stock valued at $154,952,012 over the last 90 days. Insiders own 3.50% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on LFST shares. Zacks Research lowered LifeStance Health Group from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 13th. The Goldman Sachs Group started coverage on LifeStance Health Group in a research report on Friday, June 5th. They issued a "neutral" rating and a $9.00 target price for the company. Weiss Ratings upgraded LifeStance Health Group from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, August 11th. BTIG Research raised their target price on LifeStance Health Group from $16.00 to $18.00 and gave the company a "buy" rating in a report on Wednesday, August 19th. Finally, KeyCorp boosted their price target on LifeStance Health Group from $11.00 to $13.00 and gave the stock an "overweight" rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, LifeStance Health Group has a consensus rating of "Moderate Buy" and a consensus target price of $12.38.

LifeStance Health Group Company Profile

LifeStance Health Group NASDAQ: LFST is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source